INSP logo

Inspire Medical Systems, Inc. (INSP) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

INSP, 50.13$ (piyasa değeri 2B) fiyatla Healthcare işi olan Inspire Medical Systems, Inc.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 55/100 puan alıyor.

Son analiz: 9 Şub 2026
55/100 AI Puanı Hedef $90.73 (+81.0%) PD 2B Hacim 758K

Inspire Medical Systems, Inc. (INSP) Sağlık ve Boru Hattı Genel Bakışı

CEOTimothy Herbert
Çalışanlar1246
MerkezGolden Valley, MN, US
Halka Arz Yılı2018
SektörHealthcare

Inspire Medical Systems revolutionizes sleep apnea treatment with its innovative neurostimulation technology, offering a minimally invasive alternative to traditional therapies. With a strong gross margin of 84.9% and a P/E ratio of 43.25, Inspire is poised for continued growth in the expanding OSA market.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 9 Şub 2026

Yatırım Tezi

Inspire Medical Systems presents a notable research candidate due to its innovative technology and strong market position in the growing OSA treatment space. The company's Inspire system offers a unique, minimally invasive alternative to CPAP, appealing to a significant portion of the OSA patient population. With a high gross margin of 84.9% and a P/E ratio of 43.25, Inspire demonstrates strong profitability and growth potential. Key value drivers include continued market penetration in the US and international expansion. Upcoming catalysts include ongoing clinical trials and favorable reimbursement policies. The company's focus on innovation and patient outcomes positions it for long-term success.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market Cap of $1.94B reflects investor confidence in Inspire's growth potential.
  • P/E Ratio of 43.25 indicates a premium valuation based on future earnings expectations.
  • Gross Margin of 84.9% showcases the company's efficient cost management and strong pricing power.
  • Beta of 0.72 suggests lower volatility compared to the overall market.
  • Profit Margin of 5.0% demonstrates improving profitability as the company scales.

Rakipler & Benzerleri

Güçlü Yönler

  • Innovative and minimally invasive technology.
  • Strong clinical evidence and patient outcomes.
  • High gross margins and revenue growth.
  • Dedicated focus on obstructive sleep apnea (OSA).

Zayıflıklar

  • Relatively high cost of the Inspire system.
  • Limited market penetration compared to traditional CPAP therapy.
  • Dependence on physician training and adoption.
  • Requires surgical implantation.

Katalizörler

  • Ongoing: Continued market penetration in the US and international expansion.
  • Ongoing: Positive clinical trial results and publications supporting the safety and efficacy of Inspire therapy.
  • Upcoming: Favorable reimbursement policies from insurance companies and government healthcare programs.
  • Ongoing: Development and commercialization of next-generation neurostimulation technologies.
  • Ongoing: Strategic partnerships with healthcare providers and technology companies.

Riskler

  • Potential: Competition from established CPAP therapy providers and alternative OSA treatments.
  • Potential: Changes in reimbursement policies affecting the affordability of Inspire therapy.
  • Potential: Product liability claims and regulatory challenges.
  • Ongoing: Dependence on physician training and adoption of Inspire therapy.
  • Potential: Economic downturn affecting patient affordability and healthcare spending.

Büyüme Fırsatları

  • Geographic Expansion: Inspire has the opportunity to expand its market presence internationally, targeting countries with high OSA prevalence and unmet treatment needs. This includes strategic partnerships and regulatory approvals in key markets such as Europe and Asia. The global market for sleep apnea devices is projected to grow significantly, offering a substantial addressable market for Inspire's expansion efforts. Timeline: Ongoing.
  • Product Innovation: Inspire can further enhance its product portfolio by developing next-generation neurostimulation technologies and expanding its closed-loop solution. This includes incorporating advanced sensors and algorithms to optimize therapy delivery and improve patient outcomes. Continuous innovation will strengthen Inspire's competitive advantage and attract a wider range of patients. Timeline: Ongoing.
  • Increased Market Penetration: Inspire can increase its market share in the US by expanding its sales and marketing efforts, targeting sleep centers and ENT physicians. This includes raising awareness of Inspire therapy and educating healthcare professionals about its benefits. Increased market penetration will drive revenue growth and solidify Inspire's position as a leader in the OSA treatment market. Timeline: Ongoing.
  • Strategic Partnerships: Inspire can form strategic partnerships with healthcare providers, insurance companies, and technology companies to expand its reach and improve patient access to Inspire therapy. This includes collaborations with telehealth platforms to offer remote monitoring and support services. Strategic partnerships will accelerate market adoption and enhance the patient experience. Timeline: Ongoing.
  • Clinical Data and Research: Inspire can continue to invest in clinical research to generate additional data supporting the safety and efficacy of Inspire therapy. This includes conducting long-term studies to evaluate the durability of treatment effects and identify optimal patient selection criteria. Strong clinical data will reinforce Inspire's value proposition and support reimbursement coverage. Timeline: Ongoing.

Fırsatlar

  • Expanding into international markets.
  • Developing next-generation neurostimulation technologies.
  • Increasing awareness and adoption of Inspire therapy.
  • Forming strategic partnerships with healthcare providers and insurance companies.

Tehditler

  • Competition from established CPAP therapy providers.
  • Potential changes in reimbursement policies.
  • Technological advancements in alternative OSA treatments.
  • Economic downturn affecting patient affordability.

Rekabet Avantajları

  • Proprietary neurostimulation technology protected by patents and intellectual property.
  • Established brand reputation and strong clinical evidence supporting the safety and efficacy of Inspire therapy.
  • High switching costs for patients who have undergone the Inspire implant procedure.
  • Extensive network of trained physicians and sleep centers offering Inspire therapy.

INSP Hakkında

Inspire Medical Systems, Inc., founded in 2007 and headquartered in Golden Valley, Minnesota, is dedicated to transforming the lives of individuals suffering from obstructive sleep apnea (OSA). The company develops and commercializes minimally invasive solutions, with its primary focus on the Inspire system, a neurostimulation technology designed for patients with moderate to severe OSA who are CPAP intolerant. This innovative system delivers mild stimulation to key airway muscles, keeping the airway open during sleep. Inspire's commitment extends beyond its current offerings, as it continues to develop a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway, representing a significant advancement in personalized OSA therapy. The company's geographic reach spans the United States and international markets, reflecting its ambition to establish Inspire therapy as a standard of care for OSA patients worldwide. Inspire Medical Systems has established itself as a leader in the medical device industry through its focus on innovation, patient outcomes, and physician education, positioning itself favorably against competitors by offering a unique and effective alternative to traditional OSA treatments.

Ne Yaparlar

  • Develop and commercialize the Inspire system, a neurostimulation technology for treating obstructive sleep apnea (OSA).
  • Offer a minimally invasive alternative to traditional OSA therapies like CPAP.
  • Provide a safe and effective treatment option for moderate to severe OSA patients who are CPAP intolerant.
  • Deliver mild stimulation to key airway muscles, keeping the airway open during sleep.
  • Develop a novel, closed-loop solution that continuously monitors a patient's breathing.
  • Offer hypoglossal nerve stimulation to maintain an open airway.
  • Focus on improving patient outcomes and quality of life for individuals with OSA.

İş Modeli

  • Sales of the Inspire system to hospitals, sleep centers, and ENT clinics.
  • Revenue generated from initial implant procedures and follow-up appointments.
  • Reimbursement from insurance companies and government healthcare programs.
  • Expansion into international markets through direct sales and distribution partnerships.

Sektör Bağlamı

Inspire Medical Systems operates within the medical device industry, specifically targeting the obstructive sleep apnea (OSA) market. The OSA market is experiencing significant growth, driven by increasing awareness, rising obesity rates, and an aging population. The competitive landscape includes traditional CPAP therapy providers and other medical device companies developing alternative OSA treatments. Inspire's neurostimulation technology offers a unique value proposition, positioning it as a leader in the minimally invasive OSA treatment segment. The global sleep apnea devices market is projected to reach billions of dollars in the coming years, presenting a substantial growth opportunity for Inspire.

Kilit Müşteriler

  • Patients with moderate to severe obstructive sleep apnea (OSA) who are CPAP intolerant.
  • Sleep centers and hospitals that offer OSA diagnostic and treatment services.
  • Ear, nose, and throat (ENT) physicians who specialize in OSA management.
  • Insurance companies and government healthcare programs that reimburse for OSA treatments.
AI Güveni: 72% Güncellendi: 9 Şub 2026

Finansallar

Grafik & Bilgi

Inspire Medical Systems, Inc. (INSP) hisse senedi fiyatı: $50.13 (-0.32, -0.63%)

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

INSP için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

Konsensüs hedefi: $90.73

MoonshotScore

55/100

Bu puan ne anlama geliyor?

MoonshotScore, INSP'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

En Son Inspire Medical Systems, Inc. Analizi

INSP Healthcare Hisse Senedi SSS

INSP için değerlendirilmesi gereken temel faktörler nelerdir?

Inspire Medical Systems, Inc. (INSP) şu anda yapay zeka skoru 55/100, orta puanı gösteriyor. Hisse 10.0x F/K oranıyla işlem görüyor, S&P 500 ortalamasının (~20-25x) altında, potansiyel değer sinyali. Analist hedefi $90.73 ($50.13'dan +81%). Temel güçlü yan: Innovative and minimally invasive technology.. İzlenmesi gereken birincil risk: Potential: Competition from established CPAP therapy providers and alternative OSA treatments.. Bu bir finansal tavsiye değildir.

INSP MoonshotScore'u nedir?

INSP şu anda MoonshotScore'da 55/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

INSP verileri ne sıklıkla güncellenir?

INSP fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler INSP hakkında ne diyor?

Analistler, INSP için $90.73 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($50.13) yukarı yönlü %81 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.

INSP'a yatırım yapmanın riskleri nelerdir?

INSP için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from established CPAP therapy providers and alternative OSA treatments.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

INSP'ın P/E oranı nedir?

Inspire Medical Systems, Inc. (INSP)'nın son P/E oranı 10.0, ki bu da piyasa ortalamasının altında, bu da göreli değeri gösterebilir. P/E (fiyat-kazanç) oranı, hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Bağlam için bunu sektördeki emsallerle ve S&P 500 ortalamasıyla (~20-25x) karşılaştırın. Yüksek bir P/E beklenen gelecekteki büyümeyi yansıtabilirken, düşük bir P/E değer düşüklüğünü veya azalan kazançları gösterebilir. Bu bir finansal tavsiye değildir.

INSP aşırı değerli mi, yoksa düşük değerli mi?

Inspire Medical Systems, Inc. (INSP)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. P/E oranı 10.0. Analist hedefi $90.73 (mevcut fiyattan +81%), analistlerin yukarı yönlü potansiyel gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

INSP'ın temettü verimi nedir?

Inspire Medical Systems, Inc. (INSP) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Fiyat itibarıyla Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Stock data pending update. Financial data is based on the most recent available information.
Veri Kaynakları

Popüler Hisseler